The pharmaceutical supply chain in the Middle East has long been fragmented—pharmacies juggling phone orders, hospitals navigating labyrinthine procurement processes, medication waste piling up in understocked clinics. Aumet, a Saudi healthtech company founded in 2016, thinks artificial intelligence can untangle the mess.
On May 13, the Riyadh-based startup announced it had closed a $12 million Series A round led by Emkan Capital, with participation from Qatar Development Bank, Azerbaijan's SABAH Fund, and AAIC. Strategic investors Cigalah Group and Salehiya Trading Company—both entrenched players in pharmaceutical distribution—also joined, a signal that incumbents see value in what Aumet is building. Existing backers Shorooq Partners and Right Side Capital Management returned for the round.
The capital injection comes as Aumet pushes beyond its original pharmacy-focused offering into more complex terrain: hospitals and national health systems. Whether its AI-driven procurement platform can scale across diverse regulatory environments remains an open question, but early deployments in Jordan suggest the company has found traction in at least one market.
A Crowded Cap Table with Regional Heft
Emkan Capital, a venture firm backed by Saudi Arabia's sovereign wealth apparatus, anchored the round. Qatar Development Bank brought government-backed capital from Doha, while SABAH Fund—launched just two years earlier and active across the South Caucasus, Central Asia, and parts of the Middle East—came in as a newer institutional player.
AAIC, which first wrote a check to Aumet in 2022 through its Africa Innovation & Healthcare Fund, doubled down. The presence of Cigalah Group and Salehiya Trading Company is perhaps more revealing. Both operate distribution networks that touch the same pharmacies and clinics Aumet serves, suggesting the platform has reached a level of adoption that warrants attention from traditional middlemen.
From Pharmacy Tool to National Health System Play
Aumet started in 2016 with a straightforward pitch: digitize procurement for independent pharmacies. Originally incorporated in Delaware before establishing operational headquarters in Saudi Arabia, the company built a mobile-first platform that connected small-scale buyers with suppliers, cutting out friction and phone tag.
The product suite has since splintered into three distinct offerings. Pulse, the original pharmacy tool, handles procurement automation for independent operators. Chain caters to multi-branch pharmacy groups with centralized buying needs. Enterprise—the more recent, more ambitious product—deploys AI-powered procurement systems for hospitals and government health agencies.
According to the company, the platform now processes over $1 billion in annual gross merchandise value across more than five million transactions, connecting north of 12,000 pharmacies with over 1,000 pharmaceutical suppliers. Those figures, if accurate, position Aumet as one of the larger B2B healthtech platforms operating in the region.
Jordan: A Test Case for Larger Ambitions
Aumet's Enterprise product got an early proving ground at Al-Basheer Hospital in Jordan, a public facility in Amman. The pilot apparently went well enough to catch the attention of national officials. The company secured a broader rollout with Jordan's Ministry of Health and Ministry of Digital Economy & Entrepreneurship, expanding the platform across 32 hospitals, over 500 health centers, and over 18 medical warehouses.
TechScoop, a regional tech publication, reported that the deployment led to JOD 2.3 million (roughly $3.2 million) in reduced medication waste at Al-Basheer over a three-month period. Waste reduction at that scale—if it holds across other facilities—could offer a compelling ROI story for government buyers elsewhere in the region.
The Jordan expansion received backing from Presight AI, a data analytics and AI subsidiary of G42, the Abu Dhabi-based tech conglomerate. G42's fingerprints on the deal underscore the broader appetite among Gulf investors for AI applications in traditionally analog sectors.
Where the Money Goes
Aumet says it will use the fresh capital to scale its AI capabilities, expand hospital and national health system deployments, and push into additional GCC markets. The company also flagged plans to "globalize" Pulse, its pharmacy-focused product, though it stopped short of naming specific markets beyond Qatar.
The company's fundraising trajectory shows steady, if measured, growth. It raised $7 million in a pre-Series A round back in March 2023, led by AAIC with participation from AIJ Holdings and Tijah Holdings. Earlier funding includes a $1.25 million seed round from Right Side Capital in mid-2020, along with smaller checks from 500 Startups, Plug and Play, and Techstars between 2016 and 2019.
Team size has grown accordingly. LinkedIn data suggests the company employs somewhere in the range of 51 to 200 people, though Aumet hasn't disclosed an official headcount.
The Harder Part Ahead
Digitizing pharmacy procurement is one thing. Convincing hospitals and national health ministries to overhaul entrenched procurement workflows—often governed by byzantine regulations and political considerations—is another entirely. Aumet's Jordan deployment offers proof of concept, but replicating that success across Saudi Arabia, Egypt, Oman, and beyond will test whether the company's AI infrastructure can adapt to different regulatory regimes and supplier ecosystems.
The strategic involvement of distribution giants like Cigalah and Salehiya suggests Aumet isn't trying to disintermediate the entire supply chain. Instead, it appears to be positioning itself as infrastructure that sits atop existing networks, streamlining transactions rather than replacing incumbents outright. Whether that approach scales—or whether it invites competition from those same incumbents building their own digital tools—will determine if this $12 million round was just the beginning or the high-water mark.
